Dergiler / Turkish Journal of Pediatrics / 2018 / Cilt: 60 - Sayı: 3

Birth outcomes after inadvertent use of category X drugs contraindicated in pregnancy: Where is the real risk?

Sayfa
298–305
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Individual risk assessmentand avoiding the phrase ‘CXD’ or ‘contraindicated in pregnancy’ in counselingmay help to reduce maternal concerns about medication use in pregnancy

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Drugs contraindicated in pregnancy are medicines that should be avoided bypregnant women, since they carry a concern for teratogenicity or there is noindication for their use during pregnancy.
📊
Temel Bulgular & Veri:We retrospectively analyzed prenatal drugexposure records of the pregnant patients referred to the clinical pharmacologyconsultation service in a tertiary-level university hospital from January 2007until December 2012.
💡
Sonuç & Katkı:Individual risk assessmentand avoiding the phrase ‘CXD’ or ‘contraindicated in pregnancy’ in counselingmay help to reduce maternal concerns about medication use in pregnancy
🔬Tür:Araştırma Makalesi
📍Kapsam:2012 Verileri
⚙️Değişkenler:Alan Parametreleri

Özet

Drugs contraindicated in pregnancy are medicines that should be avoided bypregnant women, since they carry a concern for teratogenicity or there is noindication for their use during pregnancy. It does not mean that exposuresto these drugs always cause harm. The aim of the present study was toinvestigate the risk of adverse outcomes following maternal exposure to thedrugs contraindicated in pregnancy. We retrospectively analyzed prenatal drugexposure records of the pregnant patients referred to the clinical pharmacologyconsultation service in a tertiary-level university hospital from January 2007until December 2012. Exposures to category X drugs (CXD) contraindicatedin pregnancy were evaluated. After the expected date of delivery, we collecteddata about pregnancy complications and the outcomes. For comparison thewomen in the exposed group (N=52) were matched with a control group(N=162) of pregnant women without teratogenic exposure. We observed onlyone baby born with a birth defect (congenital cryptorchidism) in CXD group(2.6%) and four in control group (RR 0.91; 95% CI 0.10- 7.94). The rates ofadverse pregnancy outcomes including miscarriage, preterm birth and congenitalabnormality were not significantly different from controls. However, the rateof elective termination of pregnancy was higher in women exposed to CXDwhile pregnant (RR 2.54; 95% CI 1.11- 5.80, p = 0.027). Contraceptive failureand unintended pregnancy are the reasons for inadvertent drug exposure andchoosing abortion. The high perception of teratogenic risk among pregnantwomen may cause terminations of pregnancies. Individual risk assessmentand avoiding the phrase ‘CXD’ or ‘contraindicated in pregnancy’ in counselingmay help to reduce maternal concerns about medication use in pregnancy

🔖

Bu Makaleye Atıf Yap

ÖZTÜRK, Z., ÖLMEZ, E., GÜRPINAR, T., VURAL, K. (2018). Birth outcomes after inadvertent use of category X drugs contraindicated in pregnancy: Where is the real risk?. Turkish Journal of Pediatrics, Cilt: 60 - Sayı: 3, 298–305. https://ajindex.com/articles/412114

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (18)

  1. Sinclair SM, Miller RK, Chambers C, Cooper EM. Medication safety during pregnancy: improving evidence-based practice. J Midwifery Womens Health 2016; 61: 52-67
  2. Öztürk, Z. Medication use in pregnancy and risk evaluation: Do not categorize me. 2017. Available at: http://dergipark.gov.tr/zktipb/issue/25001/322632. Accessed November 7, 2017
  3. Ramoz LL, Patel-Shori NM. Recent changes in pregnancy and lactation labeling: Retirement of risk categories. Pharmacotherapy 2014; 34: 389-395
  4. Pernia S, DeMaagd G. The new pregnancy and lactation labeling rule. PT 2016; 41: 713-715
  5. Greene MF. FDA drug labeling for pregnancy and lactation drug safety monitoring systems. Semin Perinatol 2015; 39: 520-523
  6. Pines A. Patient information leaflets: friend or foe? Climacteric 2015; 18: 663-665
  7. Cooper WO, Hickson GB, Ray WA. Prescriptions for contraindicated category X drugs in pregnancy among women enrolled in TennCare. Paediatr Perinat Epidemiol 2004; 18: 106-111
  8. Kao LT, Chen YH, Lin HC, Chung SD. Prescriptions for category D and X drugs during pregnancy in Taiwan: A population-based study. Pharmacoepidemiol Drug Saf 2014; 23: 1029-1034
  9. Song I, Choi SH, Shin JY. Trends in prescription of pregnancy-contraindicated drugs in Korea, 2007-2011. Regul Toxicol Pharmacol 2016; 75: 35-45
  10. Zomerdijk IM, Ruiter R, Houweling LM, Herings RM, Straus SM, Stricker BH. Dispensing of potentially teratogenic drugs before conception and during pregnancy: A population-based study. BJOG 2015; 122: 1119- 1129
  11. Harville EW, Wilcox AJ, Baird DD, Weinberg CR. Vaginal bleeding in very early pregnancy. Hum Reprod 2003; 18: 1944-1947
  12. Pletcher JR, Slap GB. Menstrual disorders. Pediatr Clin North Am 1999; 46: 505-518
  13. Melhado EM, Maciel JA Jr, Guerreiro CA. Headache during gestation: Evaluation of 1101 women. Can J Neurol Sci 2007; 34: 187-192
  14. Contag SA, Bushnell C. Contemporary management of migrainous disorders in pregnancy. Curr Opin Obstet Gynecol 2010; 22: 437-445
  15. Acs N, Banhidy F, Puho E, Czeizel AE. A possible dose-dependent teratogenic effect of ergotamine. Reprod Toxicol 2006; 22: 551-552
  16. Banhidy F, Acs N, Puho E, Czeizel AE. Ergotamine treatment during pregnancy and a higher rate of low birth weight and preterm birth. Br J Clin Pharmacol 2007; 64: 510-516
  17. Sedgh G, Singh S, Hussain R. Intended and unintended pregnancies worldwide in 2012 and recent trends. Stud Fam Plan 2014; 45: 301–304
  18. Lowe GD. Arterial disease and venous thr